Katsura Matsubara's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership • Q1 2025
Question
Katsura Matsubara from Nomura Securities asked for the reasons behind the weak Q1 revenue performance in the U.S. and specifically for TAKHZYRO. He also inquired about the future competitive threat to TAKHZYRO from a new market entrant.
Answer
U.S. Business Unit President Julie Kim cited the impact of Medicare Part D redesign as a factor in the overall U.S. performance. For TAKHZYRO, she stated the product remains strong and competitive based on its long-term efficacy and safety data. CFO Milano Furuta added that the Vyvanse loss of exclusivity was the biggest driver of the soft U.S. numbers and that lower channel inventory also impacted TAKHZYRO's reported sales.